Federal Register Notice: FDA is amending a 10/22 notice of the meeting of the Blood Products Advisory Committee to reflect a change in the Agenda portion of the document. Instead of hearing a presentation on the emergence of chikungunya virus infections in the Western Hemisphere and potential implications for blood transfusion safety and on the first survey of the Rapid Donor Surveillance project on Middle Eastern Respiratory Syndrome coronavirus, the committee will hear an informational presentation on Ebola virus, the potential implications for blood safety in the U.S. and FDA’s considerations on the collection of convalescent plasma for investigational use. Contact Bryan Emery or Joanne Lipkind, (240) 402-8054 or (240) 402-8129. To view this notice, click here.